Isoprenylcysteine Carboxylmethyltransferase-Based Therapy for Hutchinson–Gilford Progeria Syndrome

[Image: see text] Hutchinson–Gilford progeria syndrome (HGPS, progeria) is a rare genetic disease characterized by premature aging and death in childhood for which there were no approved drugs for its treatment until last November, when lonafarnib obtained long-sought FDA approval. However, the bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcos-Ramiro, Beatriz, Gil-Ordóñez, Ana, Marín-Ramos, Nagore I., Ortega-Nogales, Francisco J., Balabasquer, Moisés, Gonzalo, Pilar, Khiar-Fernández, Nora, Rolas, Loïc, Barkaway, Anna, Nourshargh, Sussan, Andrés, Vicente, Martín-Fontecha, Mar, López-Rodríguez, María L., Ortega-Gutiérrez, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393201/
https://www.ncbi.nlm.nih.gov/pubmed/34471675
http://dx.doi.org/10.1021/acscentsci.0c01698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393201/
https://www.ncbi.nlm.nih.gov/pubmed/34471675
http://dx.doi.org/10.1021/acscentsci.0c01698

Ejemplares similares